GUMDROP : JHMI J1099 A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephrectomy

Description:

RCC with clear-cell or predominant clear-cell histology; non-metastatic dx (M0) with pT2/G3 or G4/N0; or pT3/Gany/N0; or pT4/Gany/N0; or pTany/Gany/N1; completed nephrectomy w/i 12 weeks of registration

Link:

http://clinicaltrials.gov/ct2/show/study/NCT01235962

 

Site:

Johns Hopkins Hospital

Principal Investigator:

Hans Hammers, M.D.